Pathology of malignant melanoma, including new markers and techniques in diagnosis and prognosis

Current Opinion in Oncology

Volumn 8, Issue 2, 1996, Pages 143-151

  De Wit, Peter E J ^a   Van Muijen, Goos N P ^a   De Waal, Robert M W ^a   Ruiter, Dirk J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; HERMES ANTIGEN; INTEGRIN; MESSENGER RNA; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; PROTEINASE; TISSUE PLASMINOGEN ACTIVATOR; TUMOR MARKER; UROKINASE;

ANGIOGENESIS; CANCER DIAGNOSIS; CLINICAL ARTICLE; HUMAN; HUMAN CELL; IN SITU HYBRIDIZATION; MELANOMA; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SKIN CANCER; SKIN CARCINOGENESIS;

EID: 0030013964     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199603000-00012     Document Type: Review

References (69)

1. Wong T-Y, Suster S, Duncan LM, Mihm MC: Nevoid melanoma: a clinicopathological study of seven cases of malignant melanoma mimicking spindle and epithelioid cell nevus and verrucous dermal nevus. Hum Pathol 1995, 26:171-1 79. A detailed clinicopathologic study. The golden standard for studies aiming at the correct classification of histomorphologically impossible cases through molecular markers.
2. MacKie RM, Aitchison T, Sirel JM, McLaren K, Watt DC: Prognostic models for subgroups of melanoma patients from the Scottish Melanoma Group database 1979-86, and their subsequent validation. Br J Cancer 1995, 71:173-176.
3. Garbe C, Büttner P, Bertz J, Burg G, D'Hoedt B, Drepper H, Guggenmoos-Holzmann I, Lechner W, Lippold A, Orfanos CE, Peters A, Rassner G, Stadler R, Stroebel W: Primary cutaneous melanoma: identification of prognostic groups and estimation of individual prognosis for 5093 patients. Cancer 1995, 75:2484-2491.
4. Clark WH, Elder DE, Guerry D, Braitman LE, Track BJ, Schultz D, Synnestvedt M, Halpern AC: Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 1989, 81:1893-1904.
5. Weterman MAJ, Van Muijen GNP, Bloemers HP, Ruiter DJ: Molecular markers of melanocytic tumour progression. Lab Invest 1994, 70:593-608.
6. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995, 1:27-31. An extended review on angiogenesis in pathophysiology.
7. Kohn EC, Liotta LA: Molecular insight into cancer invasion: strategies for prevention and intervention. Cancer Res 1995, 55:1856-1862. A stimulating perspective on cancer therapies that are based on molecular insight in the processes regulating and effectuating the invasive properties of tumor and endothelial cells.
8. Danen EHJ, Van Muijen GNP, Ruiter DJ: Role of integrins as signal transducing cell adhesion molecules in human cutaneous melanoma. Cancer Surv 1995, 24:43-65. An extended review on integrins as diagnostic and prognostic markers in melanocytic tumor progression.
9. Edward M: Integrins and other adhesion molecules involved in melanocytic tumor progression. Curr Opin Oncol 1995, 7:185-191.
10. Pignatelli M, Stamp G: Integrins in tumor development and spread. Cancer Surv 1995, 24:113-127.
11. Clark EA, Brugge JS: Integrins and signal transduction pathways: the road taken. Science 1995, 268:233-239.
12. Garofalo A, Chirivi RGS, Foglieni C, Pigott R, Mortarini R, Martin-Padura I, Anichini A, Gearing AJ, Sanchez-Madrid F, Dejana E, Giavazzi R: Involvement of the very late antigen 4 integrin on melanoma in interleukin 1-augmented experimental metastases. Cancer Res 1995, 55:414-419.
13. Danen EHJ, Jansen KFJ, Van Kraats AA, Cornelissen IMHA, Ruiter DJ, Van Muijen GNP: αv-Integrins in human melanoma: gain of αvβ3 and loss of αvβ5 are related to tumor progression in situ but not to metastatic capacity of cell lines in nude mice. Int J Cancer 1995, 61:491-496.
14. Mitjans F, Sander D, Adán J, Sutter A, Martinez JM, Jäggle C-S, Moyano JM, Kreysch H-G, Piulats J, Goodman SL: An anti-αv-integrin antibody that blocks integrin function inhibits the development of a human melanoma in nude mice. J Cell Sci 1995, 108:2825-2838.
15. Danen EHJ, Ten Berge PJM, Van Muijen GNP, Van't Hof-Grootenboer AE, Bröcker E-B, Ruiter DJ: Emergence of α5β1 fibronectin- and αvα3 vitronectin-receptor expression in melanocytic tumour progression. Histopathol 1994, 24:249-256.
16. Schadendorf D, Heidel J, Gawlik C, Suter L, Czametzki BM: Association with clinical outcome of expression of VLA-4 in primary cutaneous malignant melanoma as well as P-selectin and E-selectin on intratumoral vessels. J Natl Cancer Inst 1995, 87:366-371.
17. Brooks PC, Clark RAF, Cheresh DA: Requirement of vascular integrin αvβ3 for angiogenesis. Science 1994, 264:569-571.
18. Ponta H, Sleeman J, Herrlich P: Tumor metastasis formation: cell-surface proteins confer metastasis-promoting or -suppressing properties. Biochem Biophys Acta 1994, 1198:1-10.
19. Fox SB, Fawcett J, Jackson DG, Collins I, Gatter KC, Harris AL, Gearing A, Simmons DL: Normal human tissues, in addition to some tumors, express multiple different CD44 isoforms. Cancer Res 1994, 54:4539-4546.
20. Günthert U, Stauder R, Mayer B, Terpe H-J, Finke L, Friedrichs K: Are CD44 variant isoforms involved in human tumour progression? Cancer Surv 1995, 24:19-42.
21. Van Muijen GNP, Danen EHJ, Veerkamp JH, Ruiter DJ, Lesley J, Van Den Heuvel LPWJ: Glycoconjugate profile and CD44 expression in human melanoma cell lines with different metastatic capacity. Int J Cancer 1995, 61:241-248.
22. Zhang L, Underhill CB, Chen L: Hyaluronan on the surface of tumor cells is correlated with metastatic behavior. Cancer Res 1995, 55:428-433.
23. Manten-Horst E, Danen EHJ, Smit L, Snoek M, Le Poole IC, Van Muijen GNP, Pals ST, Ruiter DJ: Expression of CD44 splice variants in human cutaneous melanoma and melanoma cell lines is related to tumor progression and metastatic potential. Int J Cancer 1995, 64:182-188.
24. De Vries TJ, Van Muijen GNP, Ruiter DJ: The plasminogen activation system in tumour invasion and metastasis. Pathol Update 1996, in press. An extended review on the components of the plasminogen activation system as diagnostic and prognostic markers in tumor progression.
25. Delbaldo C, Masouye I, Saurai J-H, Vassalli J-D, Sappino A-P: Plasminogen activation in melanocytic neoplasia. Cancer Res 1994, 54:4547-4552.
26. De Vries TJ, Quax PHA, Denijn M, Verrijp KN, Verheijen JH, Verspaget HW, Weidle UH, Ruiter DJ, Van Muijen GNP: Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression. Am J Pathol 1994, 144:70-81.
27. Stahl A, Mueller BM: Binding of urokinase to its receptor promotes migration and invasion of human melanoma cells in vitro. Cancer Res 1994, 54:3066-3071.
28. Quax PHA, Van Muijen GNP, Weening-Verhoeff EJD, Lund LR, Danø K, Ruiter DJ, Verheijen JH: Metastatic behaviour of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor and urokinase mediated matrix degradation. J Cell Biol 1991, 115:191-199.
29. Nip J, Rabbani SA, Shibata HR, Brodt P: Coordinated expression of the vitronectin receptor and the urokinase-type plasminogen activator receptor in metastatic melanoma cells. J Clin Invest 1995, 95.2096-2103.
30. Mueller BM, Yu YB, Laug WE: Overexpression of plasminogen activator inhibitor 2 in human melanoma cells inhibits spontaneous metastasis in scid/scid mice. Proc Natl Acad Sci USA 1995, 92:205-209.
31. Quattrone A, Fibbi G, Anichini E, Pucci M, Zamperini A, Capaccioli S, Del Rosso M: Reversion of the invasive phenotype of transformed human fibroblasts by anti-messenger oligonucleotide inhibition of urokinase receptor gene expression. Cancer Res 1995, 55:90-95.
32. De Vries TJ, Mooy CM, Van Balken MR, Luyten GPM, Quax PHA, Verspaget HW, Weidle UH, Ruiter DJ, Van Muijen GNP: Components of the plasminogen activation system in uveal melanoma: a clinicopathological study. J Pathol 1995, 175:59-67.
33. De Vries TJ, De Wit PEJ, Clemmensen I, Verspaget HW, Weidle UH, Brocker E-B, Ruiter DJ, Van Muijen GNP: Tetranectin and plasmin/plasmlnogen are similar distributed at the invasive front of cutaneous melanoma lesions. J Pathol 1996, in press.
34. Pötgens AJG, Westphal HR, De Waal RMW, Ruiter DJ: The role of vascular permeability factor and basic fibroblast growth factor in tumor angiogenesis. Biol Chem Hoppe-Seyler 1995, 376:57-70. An extended review on tumor angiogenesis, focusing on melanocylic tumor progression.
35. Kolber DL, Knisely TL, Maione TE: Inhibition of development of murine melanoma lung metastases by systemic administration of recombinant platelet factor 4. J Natl Cancer Inst 1995, 87:304-309.
36. Ruiter DJ, Schlingemann RO, Westphal JR, Denijn M, Rietveld FJ, De Waal RM: Angiogenesis in wound healing and tumor metastasis. Behring Inst Mitt 1993, 92:258-272.
37. Kaipainen A, Vlaykova T, Hatva E, Böhling T, Jekunen A, Pyrhönen S, Alitalo K: Enhanced expression of the tie receptor tyrosine kinase messenger RNA in the vascular endothelium of metastatic melanomas. Cancer Res 1994, 54:6571-6577.
38. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J: Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994, 79:315-328.
39. Kim KH, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993, 362:841-844.
40. Hori A, Sasada R, Matsutani E, Naito K, Sakura Y, Fujita T, Kozai Y: Suppression of solid tumour growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor. Cancer Res 1991, 51:6180-6184.
41. Pötgens AJG, Lubsen NH, Van Altena MC, Schoenmakers JGG, Ruiter DJ, De Waal RMW: Vascular permeability factor expression influences tumor angiogenesis in human melanoma lines xenografted to nude mice. Am J Pathol 1995, 146:197-209.
42. Reed JA, McNutt NS, Albino AP: Differential expression of basic fibroblast growth factor (bFGF) in melanocytic lesions demonstrated by in situ hybridization. Am J Pathol 1994, 144:329-336.
43. Graham CH, Rivers J, Kerbel RS, Stankiewicz KS, White WL: Extent of vascularization as a prognostic indicator in thin (<0.76 mm) malignant melanomas. Am J Pathol 1994, 145:510-514.
44. Barnhill RL, Busam KJ, Berwick M, Blessing K, Cochran AJ, Elder DE, Fandrey K, Karaoli T, White WL: Tumour vascularity is not a prognostic factor for cutaneous melanoma. Lancet 1994, 344:1237-1238.
45. Freeman MR, Scheck FX, Gagnon ML, Corless C, Soker S, Niknejad K, Peoples GE, Klagsbrun MK: Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: a potential role for T cells in angiogenesis. Cancer Res 1995, 55:4140-4145.
46. Smith B, Selby P, Southgate J, Pittman K, Bradley C, Blair GE: Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet 1991, 338:1227-1229.
47. Battayani Z, Grob JJ, Xerri L, Noe C, Zarour H, Houvaeneghel G, Delpero JR, Birmbaum D, Hassouri J, Bonerandi JJ: Polymerase chain reaction detection of circulating melanocytes as a prognostic marker in patients with melanoma. Arch Dermatol 1995, 131:443-447.
48. Brossart P, Schmier J-W, Krüger S, Willhauck M, Scheibenbogen C, Möhler T, Keilholz U: A polymerase chain reaction-based semiquantitative assessment of malignant melanoma cells in peripheral blood. Cancer Res 1 995, 55:4065-4068. Next to the presence of tumor cells, the burden of circulating tumor cells may also be importnat for prognosis.
49. Foss AJE, Guille MJ, Occleston NL, Hykin PG, Hungerford JL, Lightman S: The detection of melanoma cells in peripheral blood by reverse transcription-polymerase chain reaction. Br J Cancer 1995, 72:155-159.
50. Brossart P, Keilholz U, Willhauck M, Scheibenbogen G, Möhler T, Hunstein W: Hematogenous spread of malignant melanoma cells in different stages of disease. J Invest Dermatol 1993, 101:887-889
51. Hoon DSB, Wang Y, Dale PS, Conrad AJ, Schmid P, Garrison D, Kuo C, Foshag LJ, Nizze AJ, Morton DL: Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay. J Clin Oncol 1995, 13:2109-2116.
52. Sers C, Riethmüller G, Johnson JP: MUC18, a melanoma-progression associated molecule, and its potential role in tumor vascularization and hematogenous spread. Cancer Res 1994, 54:5689-5694.
53. Wang X, Heller R, Vanvoorhis N, Wayne Cruse C, Glass F, Fenske N, Berman C, Leo-Messina J, Rappaport D, Wells K, Deconti R, Moscinski L, Stankard C, Puleo C, Reintgen D: Detection of submicroscopic lymph node metastases with polymerase chain reaction in patients with malignant melanoma. Ann Surg 1994, 220:768-774.
54. Battyani Z, Xerri L, Hassoun J, Bonerandi J-J, Grob J-J: Tyrosinase gene expression in human tissues. Pigment Cell Res 1993, 6:400-405.
55. Weber J, Salgaller M, Samid D, Johnson B, Herlyn M, Lassam N, Treisman J, Rosenberg SA: Expression of the MAGE-1 tumour antigen is up-regulated by the demethylating agent 5-Aza-2′-deoxycytidine. Cancer Res 1994, 54:1766-1771.
56. Gaugler B, Van Den Eynde B, Van Der Bruggen P, Romero P, Gaforio JJ, De Plaen E, Lethé B, Brasseur F, Boon T: Human gene MAGE-3 codes for an antigen recognized on melanoma by autologous cytolytic T lymphocytes. J Exp Med 1994, 179:921-930.
57. Becker JC, Gillitzer R, Bröcker E-B: A member of the melanoma antigen-encoding gene (MAGE) family is expressed in human skin during wound healing. Int J Cancer 1994, 58:346-348.
58. Oaks MK, Hanson JP, O'Malley DP: Molecular cytogenetic mapping of the human melanoma antigen (MAGE) gene family to chromosome region Xq27-qter: Implications for MAGE immunotherapy. Cancer Res 1994, 54:1627-1629.
59. De Wit PEJ, Kerstens HMJ, Poddighe PJ, Van Muijen GNP, Ruiter DJ: DNA in situ hybridization as a diagnostic tool in the discrimination of melanoma and Spitz naevus. J Pathol 1994, 173:227-233.
60. Wiltshire RN, Duray P, Bittner ML, Visakorpi T, Meltzer PS, Tuthill RJ, Liotta LA, Trent JM: Direct visualization of the clonal progression of primary cutaneous melanoma: application of tissue microdissection and comparative genomic hybridization. Cancer Res 1995, 55:3954-3957. This study reduces the gap between in situ techniques and non-in situ biochemical tests in melanoma research.
61. Sepp NT, Li L-J, Lee KH, Brown EJ, Caughman SW, Lawley TJ, Swerlick RA: Basic fibroblast growth factor increases expression of the αvβ3 integrin complex on human microvascular endothelial cells. J Invest Dermatol 1994, 103:295-299.
62. Cornelius LA, Nehring LC, Roby JD, Parks WC, Welgus HG: Human dermal microvascular endothelial cells produce matrix metalloproteinases in response to angiogenic factors and migration. J Invest Dermatol 1995, 105:170-176.
63. Reed JA, Loganzo F, Shea CR, Walker GJ, Flores JF, Glendening JM, Bogdany JK, Shiel MJ, Haluska FG, Fountain JW, Albino AP: Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. Cancer Res 1995, 55:2713-2718.
64. Blesch A, Boßerhoff A-K, Apfel R, Behl C, Hessdoerfer B, Schmitt A, Jachimczak P, Lottspeich F, Buettner R, Bogdahn U: Cloning of a novel malignant melanoma-derived growth-regulatory protein, MIA. Cancer Res 1994, 54:5695-5701.
65. Fischer EG, Ruf W, Mueller BM: Tissue factor-initiated thrombin generation activates the signaling thrombin receptor on malignant melanoma cells. Cancer Res 1995, 55:1629-1632.
66. Shih L-M, Elder DE, Hsu M-Y, Herlyn M: Regulation of mel-CAM/MUC18 expression on melanocytes of different stages of tumor progression by normal keratinocytes. Am J Pathol 1994, 145:837-845.
67. Gutman M, Singh RK, Xie K, Bucana CD, Fidler IJ: Regulation of interleukin-8 expression in human melanoma cells by the organ environment Cancer Res 1995, 55:2470-2475.
68. Iida J, Meijne AML, Spiro RC, Roos E, Furcht LT, McCarthy JB: Spreading and focal contact formation of human melanoma cells in response to the stimulation of both melanoma-associated proteoglycan (NG2) and α4β1 integrin. Cancer Res 1995, 55:2177-2185.
69. Enenstein J, Kramer RH: Confocal microscopic analysis of integrin expression of the microvasculature and its sprouts in the neonatal foreskin. J Invest Dermatol 1994, 103:381-386.